Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the world. | Novogene is a global leader in Next-Generation Sequencing (NGS), Proteomics, and Metabolomics services, empowering researchers and organizations with cutting-edge multi-omics solutions. Since our founding in March 2011, we have remained at the forefront of innovation, delivering world-class services to advance discoveries in life sciences, healthcare, and beyond. With state-of-the-art laboratories and operations across the United States, the United Kingdom, Germany, China, Thailand, Korea, Singapore, and Japan, Novogene has established a strong global presence to support scientific advancements worldwide. At Novogene, we have built a highly skilled, interdisciplinary team, with the majority holding advanced degrees from top global institutions. Our high-throughput sequencing and high-performance computing platforms are designed to efficiently handle large-scale genomic data, meeting the evolving demands of life sciences and medical research with secure data storage and powerful bioinformatics analysis. Through extensive collaborations with leading academic institutions, hospitals, pharmaceutical companies, and agricultural enterprises, Novogene continues to shape the future of genomic research and precision medicine. As a trusted genomics partner, we are committed to empowering researchers worldwide with the technology, expertise, and solutions needed to advance genomics and improve life. | Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 45 NGS-related patents, as well as over 950 SCI articles with a total impact factor of more than 7970, including publications in first tiers journals such as Cell, Nature and Science. The UC Davis location of Novogene Corporation Inc. was opened in early 2016. We utilize Illumina platform to serve customers in North and South America, and we also offer PacBio and Nanopore services. Novogene Corporation Inc. is proud to have collaborated with scientists from the USA, Canada, Brazil, Colombia, Mexico, and so many more. We are excited to see this global collaboration and partnership growing. | Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 62 NGS-related patents, as well as nearly 20,000 SCI articles with a total impact factor of nearly 120,000, including publications in first-tier journals such as Cell, Nature and Science. As the largest NGS service provider headquartered in Beijing with branches in Hong Kong China, US, UK, Singapore, Netherlands, and Japan, Novogene was founded in 2011 and has been growing rapidly over the past few years. Novogene has genomic sequencing labs in the US (at The University of California at Davis campus), China, Singapore, and the UK (Cambridge).
NONA BIOSCIENCES
Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models. | Nona Biosciences is a Boston-based Biotechnology company specialized in fully human antibody discovery. Harbour Mice®, our proprietary technology, are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform produces human Vh single domain antibodies, providing multiple advantages for bispecific and multispecific antibody engineering | Nona Biosciences is a Boston-based Biotech company specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection. Nona Biosciences can provide comprehensive antibody discovery services from Idea to IND, which range from Beacon® Single B Cell Cloning, display technology to functional screening, characterization, in vivo efficacy assessment, antibody engineering, and CMC for clinical candidate generation. | Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models. Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models.
NeoBiotechnologies
NeoBiotechnologies is a US-based biotechnology company established in 2013 to produce monoclonal antibodies for research, diagnostics, and therapeutics. As an original manufacturer, NeoBiotechnologies manages the entire antibody production process and offers over 20,000 monospecific antibodies validated for applications in oncology, immunology, neuroscience, and metabolism.
Navinci
Navinci is a Swedish biotech company that develops and markets in situ proximity ligation assays to detect proteins, their interactions, and modifications in tissue and cell samples, with focus on immuno-oncology research and drug development.
Navigate BioPharma Services
We design innovative biomarker solutions and customized validations based on intended use for clinical development from exploratory to regulated. Our approach is technology agnostic, meaning that we have a selection of platforms and techniques to ensure that you get the right answers. Our teams can apply our genomic, flow, digital pathology, or ligand binding analysis methods for across the spectrum of drug development and manufacturing applications. We collaborate with our clients to achieve shared goals. We offer targeted solutions, end-to-end support, and quality oversight to mitigate the risks and challenges of the regulatory process. Quality is embedded in all of our activities and is owned by each individual, to ensure we do what is right, not just when others are watching. This is the cornerstone of our positive interactions with regulators including EMA, HGRAC, FDA, and CDC. Our deep disease knowledge and team of highly-trained specialists can help you determine which platform will provide the best assessment for your intended use. We know that there are complexities and nuances to the diseases you are developing therapies for, and aligning the questions you need answered with the right analytical method(s) for a particular patient population is critical.
Nacalai USA, Inc.
Nacalai USA is located in San Diego and is a subsidiary of Nacalai Tesque, a reagent company based in Kyoto, Japan. We provide a wide range of research products in the Life Science and Analytical Chemistry fields, including various reagents, 3D cell culture vessels, IHC and protein research related products, HPLC columns, and research chemicals. Our mission is to propose and provide products that enable researchers to conduct their research with ease. If you are having trouble with your research or would like to find products new to you, please stop by our booth!
MS Validated Antibodies GmbH
MS Validated Antibodies is devoted to delivering optimal monoclonal antibodies for immunohistochemistry and to provide the users with a unique product documentation enabling them to better know their antibodies.
MP Biomedicals
MP Biomedicals is a global leader in life sciences and diagnostics, providing high-quality research tools and reagents to support cancer research, drug discovery, and molecular biology applications. With a comprehensive portfolio spanning nucleic acid extraction, cell culture, immunoassays, and protein analysis, we empower scientists with reliable solutions for advancing biomedical breakthroughs. Our commitment to innovation and quality ensures researchers have the resources they need to drive discoveries from bench to bedside.
MOSS
Since 1990, MOSS Inc. has specialized in producing high-quality, liquid-stable immunoassay reagents, including substrates, conjugates and other critical assay components. Our core technology of liquid stabilization and efficient processes in bulk manufacturing, along with our collaborative partnership approach helps us meet individual customer needs from assay development to production. Most products are stable for 36-48 months and produced in large scale at our facility in MD within ISO-9001-2015 guidelines, ensuring exceptional sensitivity, low backgrounds, and lot-to-lot consistency. MOSS products are supplied to leading manufacturers and select distributors worldwide within the diagnostics, pharma, biotechnology and veterinary diagnostic industries. | MOSS delivers the world’s first AI-assisted DAW —powered by our AI Co-producer engine that automatically analyzes, mixes, and masters audio through natural language commands. By integrating intelligent production tools with an intuitive mobile workflow, MOSS enables anyone to create studio-quality music.
Miltenyi Biotec B.V. & Co. KG
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative technologies enable solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 4,500 employees in 28 countries.